Matthew Gianferante M.D., M.P.H.

Education

Pfeiffer University 2001-2005 - Bachelor of Science in Biology and Chemistry
Uniformed Service University - 2007-2011 - Doctorate of Medicine
Tufts Floating Hospital for Children - 2011-2014 - Pediatric Internship and Residency
Pediatric Hematology/Oncology Fellowship National Capital Consortium WRNMMC - 2014-2017
Uniformed Service University - Master of Public Health - 2016-2017

Biography

CDR Matthew Gianferante is currently a Staff Clinician at the Clinical Genetics Branch at the National Cancer Institute (NCI). He obtained his M.D. at the Uniformed Services University of the Health Sciences (USU) and then completed a pediatric residency at Tufts Floating Hospital for Children, Boston, Massachusetts, a pediatric hematology oncology fellowship at Walter Reed National Military Medical Center, Bethesda, Maryland, and a master’s in public health with a concentration in epidemiology and biostatistics from USU.

At the Clinical Genetics Branch at NCI, CDR Gianferante studies the germline genetics of pediatric cancers including osteosarcoma. He also focuses on gene discovery and genotype-phenotype characterization of people with Diamond Blackfan anemia, a bone marrow failure syndrome.

Career Highlights: Positions, Projects, Deployements, Awards and Additional Publications

Gianferante, DM, Berndt S, Mirabello L. Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. Cancer Epidemiology. 2023, August. PMID: 37596165

Cole S, Giri N, Blanche P, Gianferante DM. Variable Clinical Features in a Large Family With Diamond Blackfan Anemia Caused by a Pathogenic Missense Mutation in RPS19. Frontiers in Genetics. 2022, July. PMID: 35923690.

Gianferante DM, Cole S, Zhu B, Mirabello L. Osteosarcoma: a Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017. Cancer. 2022, March. PMID: 35226758.

Gianferante DM, Kim J, Stewart D, Mirabello L. Frequency of pathogenic germline variants in cancer-susceptibility genes in the Childhood Cancer Survivor Study. JNCI Cancer Spectr. 2021, April. PMID: 34308104.

Gianferante DM, Wlodarski MW, Atsidaftos E, Da Costa L, Goldman FD, Hussain M, Kattamis A, Leblanc T, Lipton JM, Niemeyer CM, Pospisilova D, Quarello P, Ramenghi U, Sankaran VG, Vlachos A, Volejnikova J, Alter BP, Savage SA, Giri N. Genotype-phenotype association and variant characterization in Diamond-Blackfan anemia caused by pathogenic variants in RPL35A. Haematologica, 2020, April. PMID: 32241839.

Mirabello L, Zhu B, Koster R, Karlins E, Gianferante DM, Spector LG, Morton LM, Karyadi D, Armstrong GT, Gapstur S, Carter B, Hoover RN, Chanock SJ, Savage SA. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma. JAMA Oncol, 2020 March. PMID: 32191290.

Gianferante DM, Mirabello L. Whole-exome sequencing of NBCCS families and review of Human Gene Mutation Database PTCH1 mutation data. Mol Genet Genomic Medicine, 2018 Nov. PMID:30411536

Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma – connecting aetiology, biology, and therapy. Nature Review Endocrinology, 2017 Aug; 13(8):480-491. PMID: 28338660.

Coughlan D, Gianferante DM, Harlan LC. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. Pediatr Hematol Oncol, 2017 Oct; 1-11. PMID: 29039999

Groomes, Gianferante DM, Lieuw. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein. Pediatr Blood Cancer 2016 May, 922-4. PMID: 26739399.